Summit Therapeutics PLC (LON:SUMM) plans to present recent successful studies of its ridinilazole treatment for C. difficile infection (CDI) at the infectious disease conference IDWeek 2018 in San Francisco.
The company, which is on track to begin Phase III clinical trials of ridinilazole in the first quarter of next year, will present previous studies showing that the precision antibiotic can target C. Diff bacteria without also damaging the natural gut flora and that it is better than the current gold standard, vancomycin.
READ: Ridinilazole leading the way as Summit Therapeutics pivots to antibiotics
Dr David Roblin, president of R&D of Summit, said the primary endpoint of the Phase II trial will measure how ridinilazole can treat CDI and reduce recurrent CDI.
“If the phase III clinical trial results are positive, we believe these measures would differentiate ridinilazole in CDI and support its front-line use,” he said.
IDWeek started on Wednesday and runs until Sunday.